Explainer: What we know about China-made vaccines – world news

Explainer: What we know about China-made vaccines – world news

China was ahead of the global race to develop a coronavirus vaccine with the largest number of candidates in the later stages of trials earlier this year, and although there were first approvals for homemade injections for the general public on Thursday, there were no detailed efficacy data.

Here’s what we know about China’s vaccine development, efficacy data, and approval schedule.

What is the most advanced?

Five vaccines from Sinovac Biotech, China National Pharmaceutical Group (Sinopharm), CanSinoBIO and Chinese Academy of Sciences are in late clinical trials. None of them have disclosed detailed efficacy data.

Authorities approved the vaccine developed by Sinopharm’s Beijing subsidiary, and approved it on Thursday the day after the developer said it had 79.34{74ca91e3bee52d91843c282edd75c0800a88a3d8744a3a1c83b7ba867058fc3c} efficacy without providing details in an interim analysis of the phase 3 trial.

The efficacy figure is lower than the 86{74ca91e3bee52d91843c282edd75c0800a88a3d8744a3a1c83b7ba867058fc3c} share of the same vaccine released by the UAE on December 9, according to preliminary data.

Sinopharm executives did not disclose specific schedules on Thursday and said detailed data would be released later.

Sinovac’s candidate also showed a variety of efficacy readings. Late-stage data for coronavirus injections in Turkey showed a 91.25{74ca91e3bee52d91843c282edd75c0800a88a3d8744a3a1c83b7ba867058fc3c} success rate, and researchers in Brazil said its efficacy was between 50{74ca91e3bee52d91843c282edd75c0800a88a3d8744a3a1c83b7ba867058fc3c} and 90{74ca91e3bee52d91843c282edd75c0800a88a3d8744a3a1c83b7ba867058fc3c}.

Brazil expects to release efficacy data for CoronaVac by January 7 after three delays.

CanSinoBIO plans to submit clinical trial results for the vaccine to Mexican authorities next week, said Mexico’s chief health official.

How many people have been vaccinated?

Although China was slower than many other countries in approving the Covid-19 vaccine, it has been vaccinating its citizens for months with three different injections undergoing late-stage trials.

China launched an emergency use program in July targeting essential workers and people at high risk of infection, with two vaccines from Sinopharm and more than 4.5 million doses of CoronaVac from Sinovac.

In anticipation of greater transmission risk during winter, the program has been strengthened over the past month.

The South China Morning Post newspaper reported that China will vaccinate as many as 50 million people ahead of New Year’s Day in mid-February.

China has also approved CanSinoBIO’s military vaccine, and the vaccine has been given to about 40,000 to 50,000 people, a CanSinoBIO executive said on Nov. 28.

Which technology is used?

Sinopharm and Sinovac’s vaccines are based on traditional techniques to trigger an immune response using inactivated or dead viruses that cannot replicate in human cells.

The overall incidence of side effects from the COVID-19 vaccination is similar to that of other inactivated vaccines, and the incidence of relatively serious side effects such as allergies is about 1 in 2 million, according to national health department official Zeng Yixin on Thursday. .

Who buys Chinese vaccines?

The UAE became the first country this month to open a Chinese vaccine to the public.

Pakistan announced a 1.2 million capacity purchase agreement with Sinopharm on Thursday.

Sinovac’s CoronaVac shots were signed in Brazil, Indonesia, Turkey, Chile and Singapore. It is also negotiating supply with Malaysia and the Philippines.

CanSinoBIO has a supply contract with Mexico.

President Xi Jinping has pledged to make China’s vaccines a global public good.

Staff Team

Related Posts

Read also x